top of page

Shire gets extended Marketing Authorisation for Revestive

The European Commission has granted an extension of the Market Authorisation for Shire’s Revestive (teduglutide) 5 mg powder and solvent for injection for the treatment of patients aged one year and above with Short Bowel Syndrome (SBS).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page